PERTH, Australia, March 21/PRNewswire/ -- Ozgene Pty Ltd (Perth, Australia) announced this week that it has reached a final milestone in one it's drug target validation projects for NV Organon (The Netherlands).

This milestone marks the successful completion of the first project out of a series of studies undertaken between Ozgene and Organon.

The contact research undertaken by Ozgene will form the basis for further studies by the Dutch pharmaceutical company.

"We are very excited to deliver these results to Organon and are looking forward to the continuing collaboration between Ozgene and Organon" commented Dr Frank Koentgen (Director and CEO of Ozgene).

"We are happy with the progress achieved and look forward to the results of our cooperation with Ozgene" said Ton Rijnders, VP Research, N.V. Organon.

This press release is provided in good-faith by Chiltern Magazine Services Ltd ("CMS") as a service to users. Whilst every care is taken in sourcing and preparing material included here, any error or incorrect content cannot form the basis for any legal action against the site-owner. Users are advised to check the accuracy of any statements before relying upon them. Likewise, any forward-looking statements made by the author of the press release should be treated as such.

For full details, please email keithw@cmsinfo.com